New Delhi, July 13 -- that private capital, structured differently than traditional VC, could move cancer research faster than the existing system.

Yosemite has now opened the first close of its second fund, targeting $350 million, Jobs confirmed in an interview with TechCrunch published Friday. The fund will extend a portfolio that already spans roughly 25 companies across both of Yosemite's funds, backed by a team of 17 people and a model that Jobs describes as moving faster than he expected. "I didn't expect Yosemite to be moving this fast," he told the outlet.

The firm's structure distinguishes it from most oncology investors. One third of Yosemite's capital is reserved for companies the firm creates itself, typically by identifying...